作者: Qu, Alice ; El Khoury, Antoine C ; Saade, Elie ; Willame, Corinne ; Catillon, Maryaline ; Gauthier-Loiselle, Marjolaine ; Neary, Maureen P ; Cloutier, Martin ; Geurtsen, Jeroen ; Ahmad, Nina

INTRODUCTION:

Little is known about the risk of invasive E. coli disease (IED) after elective urologic procedures. We estimated the risk of IED after selected urologic procedures in patients with or without antibiotic prophylaxis, and in controls with no urologic or other surgical procedures.

METHODS:

The Komodo Research Database (01/01/2021-06/30/2023) was used to identify patients ≥ 60 years old with selected urological procedures (index: first urologic procedure date) and randomly selected controls without surgical procedures (index: random date). Patients with urologic procedures were classified into two cohorts based on whether or not they received antibiotic prophylaxis within 14 days prior to and on index date. Entropy balancing adjusted for differences between groups in selected patient characteristics over 6 months pre-index (baseline). IED rates within 30 days post-index were assessed based on recorded diagnosis of E. coli sepsis (ICD-10-CM: A41.51); odds ratios (OR) were estimated using weighted logistic regression. Sensitivity analyses within 90 days and using broader claims-based algorithm for IED were performed.

RESULTS:

Overall, 141,418 patients had urologic procedures with antibiotic prophylaxis, 200,062 had them without antibiotic prophylaxis, and 424,254 had no procedures. Within 30 days post-index, IED rates were 0.48% and 0.72% among patients with or without antibiotic prophylaxis, respectively, vs. 0.02% among those without any procedures. Among patients with urologic procedures, > 70% of IED events occurred within 30 days. Patients who had urologic procedures without prophylaxis had a higher risk of developing IED than those with prophylaxis (OR = 1.50, 95% confidence interval [CI: 1.37-1.65]), while patients without any procedures had a lower risk than those with urologic procedures and prophylaxis (OR = 0.04, 95% CI [0.03-0.05]). Similar results were obtained in sensitivity analyses.

CONCLUSIONS:

Urologic procedures were associated with an increased IED risk even with antibiotic prophylaxis. Results suggest an unmet need for additional preventative measures to reduce the burden of IED after urologic procedures.

2025-01-01·Targeted Oncology

Post-Metastasis Survival of Patients with High-Risk Localized and Locally Advanced Prostate Cancer Undergoing Primary Treatment in the United States: A Retrospective Study

Article

作者: Mundle, Suneel D ; Fernandes, Luis ; Freedland, Stephen J. ; Mir, Carmen ; Buyukkaramikli, Nasuh ; Pan, Feng ; McCarthy, Sharon A. ; Yang, Lingfeng ; De Solda, Francesco ; Labson, Daniel ; Freedland, Stephen J ; McCarthy, Sharon A ; Mundle, Suneel D.

BACKGROUND:

Patients with high-risk localized and locally advanced prostate cancer (HR-LPC/LAPC) have increased risk of metastasis, leading to reduced survival rates. Segmenting the disease course [time to recurrence, recurrence to metastasis, and post-metastasis survival (PMS)] may identify disease states for which the greatest impacts can be made to ultimately improve survival.

OBJECTIVE:

Evaluate real-world PMS of patients with HR-LPC/LAPC who received primary radical prostatectomy (RP) or radiotherapy (RT) with or without androgen deprivation therapy (ADT).

PATIENTS AND METHODS:

Electronic health records from an oncology database were used to assess PMS. Risk of death was estimated using the Kaplan-Meier method. Hazard ratios (HRs) were used to analyze the impact of treatment and time to metastasis (TTM) on PMS. Standardized mortality ratios (SMRs) were calculated for patients with HR-LPC/LAPC versus the US general male population.

RESULTS:

Overall, 5008 patients with HR-LPC/LAPC were identified, and 1231 developed metastases after primary treatment (RP, n = 885; RT only, n = 262; RT+ADT, n = 84). Age-adjusted PMS HR between the RP and RT only cohorts was 1.19 (p = 0.077) and between RP and RT+ADT cohorts was 1.32 (p = 0.078). TTM was unrelated to PMS in unadjusted (HR 1.01, p = 0.2) and age-adjusted models (HR 0.99, p = 0.3). Relative to pre-metastasis SMRs, post-metastasis SMRs increased eightfold and fivefold in patients treated with RP and RT±ADT, respectively.

CONCLUSIONS:

PMS was unrelated to TTM in patients with HR-LPC/LAPC, suggesting PMS may be independent of the trajectory to development of metastases. Given PMS may be a fixed length of time, delaying the development of metastasis may improve survival in patients with HR-LPC/LAPC.

2024-12-31·Hematology

Optimizing treatment sequencing in multiple myeloma: a novel model to predict survival outcomes

Article

作者: Mendes, João ; Petrucci, Maria Teresa ; Entrala Cerezo, Cristina ; Armeni, Patrizio ; Bringhen, Sara

OBJECTIVE:

Patients with multiple myeloma (MM) typically require multiple regimens and become harder to treat with each line of treatment. Furthermore, there is a lack of direct comparative clinical trial data to guide effective treatment sequencing. A novel model is described comparing alternative MM treatment sequences to optimize patient outcomes.

METHODS:

The model compares treatment sequences and outcomes for adults with newly diagnosed transplant-eligible (TE) or transplant-ineligible (TIE) MM across four treatment lines (first-line [FL] to fourth-line [4L]). Inputs are derived from patient-level data from clinical trials and indirect treatment comparisons. We report a base case prediction using data representing clinical practice in Italy.

RESULTS:

For FL TE, overall survival (OS) and progression-free survival (PFS) were greatest for FL regimens containing daratumumab; OS ranged from 11.80-18.10 years. PFS ranged from 4.82-13.42 years (FL) to 0.66-6.03 years (second-line [2L]), 0.81-1.76 years (third-line [3L]), and 0.69-0.72 years (4L). For FL TIE, OS rates were greater for treatment sequences with FL daratumumab vs. sequences with either 2L or no daratumumab (OS ranging from 5.95-10.61 years). PFS was greatest for FL daratumumab regimens in the TIE group, with PFS ranging from 2.12-7.48 years (FL), 0.53-4.73 years (2L), 0.63-1.17 years (3L), and 0.42 years (4L).

DISCUSSION:

This novel model demonstrates that using the most effective treatment in FL optimizes treatment sequencing and clinical outcomes for patients.

CONCLUSION:

The optimal MM treatment sequences begin with daratumumab-containing regimens in FL and improve outcomes compared with alternative sequences.

项与 Janssen Global Services LLC 相关的新闻（医药）

2024-04-18

·PRNewswire

Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight

The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness. Moreover, the radioimmunoassay market is expected to expand due to numerous ongoing research endeavors in this domain, partnerships between healthcare providers, researchers, and industry stakeholders, as well as strategic collaborations. These factors are poised to enhance the overall growth of the radioimmunoassay market from 2024 to 2030. LAS VEGAS, April 18, 2024 /PRNewswire/ -- DelveInsight's Radioimmunoassay Market Insights report provides the current and forecast market analysis, individual leading radioimmunoassay companies' market shares, challenges, radioimmunoassay market drivers, barriers, trends, and key market radioimmunoassay companies in the market. Key Takeaways from the Radioimmunoassay Market Report As per DelveInsight estimates, North America is anticipated to dominate the global radioimmunoassay market during the forecast period. As per the analysis, the global radioimmunoassay market was valued at USD 523.98 million in 2023. Notable radioimmunoassay companies such as DIAsource, MP BIOMEDICALS, Merck KGaA, Tecan Trading AG, Svar Life Science, Institute of Isotopes Co. Ltd., PerkinElmer Inc., Danaher Corporation, and several others, are currently operating in the radioimmunoassay market. To read more about the latest highlights related to the radioimmunoassay market, get a snapshot of the key highlights entailed in the Global Radioimmunoassay Market Report Radioimmunoassay Overview Radioimmunoassay stands as a groundbreaking technique in the field of medicine and biology, revolutionizing the way researchers detect and measure tiny concentrations of biological substances. Developed in the 1950s by Dr. Rosalyn Yalow and Dr. Solomon Berson, this method uses the specific binding of antibodies to antigens to quantify substances like hormones, enzymes, and drugs. In RIA, a known radioactive substance is added to a sample containing the substance of interest. Then, an antibody that recognizes the substance binds to it, forming a complex. The amount of radioactivity in the complex is directly proportional to the concentration of the substance in the sample, allowing for highly sensitive measurements in the picomolar to nanomolar range. This remarkable precision has made RIA indispensable in diagnosing conditions such as thyroid disorders, diabetes, and various hormonal imbalances. Furthermore, the versatility of Radioimmunoassay extends beyond clinical settings, finding applications in research laboratories worldwide. Scientists rely on RIA to unravel intricate mechanisms of disease progression, monitor drug levels in patients, and investigate the role of hormones in physiological processes. Its ability to detect substances in minute quantities with high accuracy has propelled advancements in fields ranging from pharmacology to endocrinology, shaping our understanding of health and disease at a molecular level. Despite the emergence of newer technologies, the enduring legacy of Radioimmunoassay continues to underpin critical medical discoveries, demonstrating the enduring impact of this pioneering technique in modern science. Radioimmunoassay Market Insights In 2023, North America dominated the radioimmunoassay market, primarily due to several factors. These include a substantial patient population dealing with Sexually Transmitted Diseases (STDs), cancer, and other ailments, a robust environment for product development and launches, and the strong presence of key market players in the region. For instance, in 2019, it was estimated by the Centers for Disease Control and Prevention (CDC) that over 1.1 million people aged 13 and above were living with HIV in the US, while around 1.75 million new cancer cases were reported. Additionally, data from the American Thyroid Association in 2019 suggested that roughly 20 million Americans suffer from some form of thyroid disease, with over 12 percent expected to develop it during their lifetime. Furthermore, the US government's significant investment of USD 650 million in rapid diagnostic testing, as announced by the US Department of Health and Human Services in 2021, further underlines the favorable conditions for the radioimmunoassay market's growth in the region. Consequently, these factors are anticipated to drive the expansion of the radioimmunoassay market in North America throughout the forecast period spanning from 2024 to 2030. To know more about why North America is leading the market growth in the radioimmunoassay market, get a snapshot of the Radioimmunoassay Market Outlook Radioimmunoassay Market Dynamics The radioimmunoassay market dynamics have been steadily evolving, driven by a myriad of factors shaping the healthcare landscape. One of the key drivers is the growing prevalence of chronic diseases such as cancer, cardiovascular disorders, and diabetes. As healthcare providers seek more efficient and accurate diagnostic tools, radioimmunoassay offers a reliable method for measuring minute quantities of substances, including hormones, enzymes, and drugs, in blood samples. This demand for precise diagnostic solutions has propelled the radioimmunoassay market forward, as clinicians rely on these tests for early detection, disease monitoring, and treatment optimization. Moreover, technological advancements have played a pivotal role in the expansion of the radioimmunoassay market. Automation and miniaturization have enhanced the efficiency of RIA tests, reducing turnaround times and improving accuracy. Additionally, the advent of novel biomarkers and reagents has widened the scope of applications for radioimmunoassay, further fueling market growth. With an increasing focus on personalized medicine, there is a rising need for tailored diagnostic approaches, a demand that the versatility and sensitivity of radioimmunoassays are uniquely positioned to fulfill. As such, the radioimmunoassay market continues to demonstrate resilience and promising prospects amidst the evolving landscape of healthcare needs and technological innovation. Get a sneak peek at the radioimmunoassay market dynamics @ Radioimmunoassay Market Dynamics Analysis Radioimmunoassay Market Assessment Radioimmunoassay Market Segmentation Radioimmunoassay Market Segmentation By Product Type: Analyzers And Reagents & Kits Radioimmunoassay Market Segmentation By Application: Research And Clinical Diagnostics Radioimmunoassay Market Segmentation By End User: Hospitals, Clinical Diagnostic Laboratories, Pharmaceutical Industries, and Others Radioimmunoassay Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the radioimmunoassay market are set to emerge as the trendsetter explore @ Radioimmunoassay Companies Table of Contents Interested in knowing the radioimmunoassay market by 2030? Click to get a snapshot of the Radioimmunoassay Market Trends Related Reports Cancer Therapy Market Cancer Therapy Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer therapy companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, Elekta AB, Varian Medical Systems, Inc., Accuray Incorporated, Pyrexar Medical, Eckert & Ziegler, IBA, Panacea Medical Technologies Pvt. Ltd., among others. Oncology Drugs Market Oncology Drugs Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key oncology drugs companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, BAYER AG., Celldex Therapeutics Inc., Alaunos Therapeutics, Inc., Astellas Pharma Inc., Genentech, Inc., Sandoz International GmbH, and BeiGene, among others. Cancer Biomarkers Market Cancer Biomarkers Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer biomarkers companies, including F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMérieux SA, BD, Merck Millipore, Agilent Technologies, Myriad Genetics, Sysmex Corporation, Hologic, Inc., Quest Diagnostics, Centogene N.V., PerkinElmer, Inc., Siemens Healthineers, Exact Sciences, R&D Systems, Inc., BioVision, Inc., among others. Intratumoral Cancer Therapies Market Intratumoral Cancer Therapies Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, along with emerging drugs and key intratumoral cancer therapies companies, including Daiichi Sankyo, Amgen, Idera Pharmaceuticals, Philogen, among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

免疫疗法ASCO会议

2023-03-02

·PRNewswire

Foundation Fighting Blindness to honor Doug Zarkin of Pearle Vision and Avi Kaner of Morton Williams Supermarket at 2023 Gala Night for Sight

The May 11th gala will raise awareness and fund research leading to treatments and cures for blinding retinal diseases. COLUMBIA, Md., March 2, 2023 /PRNewswire/ -- The Foundation Fighting Blindness, the world's leading organization committed to finding treatments and cures for blinding retinal diseases, presents its prestigious Visionary Award to Doug Zarkin, Vice President and Chief Marketing Officer of Pearle Vision and Avi Kaner, Co-Owner of Morton Williams Supermarkets through its annual gala, Night for Sight. Taking place on Thursday, May 11 at 6 p.m. ET at The Lighthouse at Chelsea Piers in Manhattan, Night for Sight will celebrate beacons of the fashion, finance, and food industries. The Foundation will honor Doug Zarkin for his commitment to improving and supporting the vision industry through Pearle Vision, partnering with other nonprofits, providing high quality eyecare to children, as well as supporting others in the vision care space. Mr. Zarkin represents growth and compassion in the vision community and the Foundation is honored to recognize him at its annual gala in May. The Foundation is also proud to honor Avi Kaner for his leadership and commitment to the community through Morton Williams Supermarkets, his work as the elected Second Selectman (Deputy Mayor) of Westport, Connecticut, and his philanthropic efforts globally. Mr. Kaner embodies the Foundation's values of accessibility and equitability through his efforts, and they are excited to recognize him through Night for Sight. "The Foundation Fighting Blindness is excited to be partnering with Doug Zarkin and Avi Kaner through Night for Sight," said Peter Ginsberg, chief operating officer of the Foundation Fighting Blindness. "Their visionary leadership in their industries and their support of the Foundation's vision-saving efforts make them exemplary Visionary Award honorees. In celebrating these two leaders, the Foundation will highlight our shared goals and our efforts to be beacons of hope for those in the vision community." Thank you to Visionary Champion National Partner, Janssen Global Services, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and Night for Sight Beacon Sponsor, Libertas Funding. Individual tickets to Night for Sight are $1,000, and Next Generation (under age 35) are $750. Sponsorship opportunities are available and range from $2,500 to $100,000. For ticket and sponsorship information, visit Give.FightingBlindness.org/NightforSight or contact Katie Van Benschoten at [email protected] or 212-961-6881. About the Foundation Fighting Blindness Established in 1971, the Foundation Fighting Blindness is the world's leading private funding source for retinal degenerative disease research. The Foundation has raised more than $891 million toward its mission to prevent, treat, and cure blindness caused by retinitis pigmentosa, macular degeneration, Usher syndrome and the spectrum of blinding retinal diseases. Visit FightingBlindness.org for more information. SOURCE Foundation Fighting Blindness

高管变更

2023-02-21

·PRNewswire

Foundation Fighting Blindness to Host their Spring VisionWalks

These VisionWalk events taking place this spring will raise awareness and fund research finding treatments and cures for blinding retinal diseases. COLUMBIA, Md., Feb. 21, 2023 /PRNewswire/ -- The Foundation Fighting Blindness, the world's leading organization committed to finding treatments and cures for blinding retinal diseases, will host their Spring VisionWalk events across the country starting in February and ending in June. These fun, family-friendly Walks are an opportunity for communities to come together to raise awareness and funds for the Foundation's mission. The Foundation's VisionWalk program includes more than 20 Walks this spring, with the first taking place in Arizona on Saturday, February 25, 2023. VisionWalk participants are encouraged to fundraise by walking individually or as a team. On Walk day, participants will gather to celebrate the blindness community with entertainment, kid's activities, refreshments, and more. "This spring's VisionWalks will celebrate our Foundation Fighting Blindness community across the United States," says Michele DiVincenzo, vice president, events. "We look forward to uniting with our VisionWalk supporters who show their unwavering dedication to our mission by walking and fundraising." Since its inception in the Spring of 2006, over 200,000 walkers, donors, and corporate sponsors have raised more than $64 million through VisionWalk. These funds have enabled the Foundation to advance research for treatments and cures from the laboratory to the patients who need them. Vision science is making great strides — today, more than 40 potential treatments are in clinical trials — but there is still more work to do. Thank you to the VisionWalk National Presenting Sponsor, Spark Therapeutics, and the Visionary Champion National Partners, Janssen Global Services, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and Samsung. Join the tens of thousands of people who are taking important steps toward treatments and cures by participating in a VisionWalk near you. Register for your local Walk today by visiting, . For additional information, contact Michele DiVincenzo at [email protected] or (847) 549-1523. About the Foundation Fighting Blindness Established in 1971, the Foundation Fighting Blindness is the world's leading private funding source for retinal degenerative disease research. The Foundation has raised more than $891 million toward its mission of accelerating research for preventing, treating, and curing blindness caused by retinal degenerative diseases including: retinitis pigmentosa, age-related macular degeneration, Usher syndrome, and Stargardt disease. Visit for more information. SOURCE FOUNDATION FIGHTING BLINDNESS

100 项与 Janssen Global Services LLC 相关的药物交易

登录后查看更多信息

100 项与 Janssen Global Services LLC 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年05月06日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

临床1期

临床2期

临床3期

批准上市

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

乌司奴单抗 ( IL-12 x IL-23 )	克罗恩病更多	批准上市
奥沙米特 ( H1 receptor )	超敏反应更多	批准上市
酮色林 ( 5-HT2 receptor )	高血压更多	批准上市
达芦那韦考比司他 ( CYP3A x HIV-1 pol )	HIV感染更多	批准上市
恩曲他滨/盐酸利匹韦林/富马酸磷丙替诺福韦 ( RT )	HIV感染更多	批准上市